本文選題：活血祛濕方 + 純化高脂飼料��； 參考：《中國(guó)實(shí)驗(yàn)方劑學(xué)雜志》2016年07期

【摘要】：目的:觀察不同劑量活血祛濕方對(duì)純化高脂飼料誘導(dǎo)的大鼠非酒精性脂肪性肝炎(NASH)模型的治療作用,探討活血祛濕方治療NASH的作用機(jī)制。方法:純化高脂飼料制備Wistar大鼠NASH模型8周,隨機(jī)分為羅格列酮組(3 mg·kg-1·d-1),活血祛濕方組高、中、低劑量組(32,16,8 g·kg-1·d-1)及模型組,另設(shè)正常組。第9周開(kāi)始ig給藥;正常組及模型組均給予等量生理鹽水ig。藥物干預(yù)4周后行血清生化指標(biāo),懫用比色法檢測(cè)血清丙氨酸氨基轉(zhuǎn)移酶(ALT),天門(mén)冬氨酸氨基轉(zhuǎn)移酶(AST),甘油三酯(TG),總膽固醇(TC)及高密度脂蛋白膽固醇(HDL-C)含量,放射免疫法檢測(cè)血清空腹血糖(FBG),空腹胰島素(FINS),酶聯(lián)免疫吸附法(ELISA)法檢測(cè)炎癥因子腫瘤壞死因子-α(TNF-α),白細(xì)胞介素-10(IL-10)及IL-6;檢測(cè)肝組織中超氧化物岐化酶(SOD)活性及丙二醛(MDA)含量;蘇木素-伊紅(HE)染色觀察肝臟組織病理學(xué)變化;卵白素-生物素-酶復(fù)合物染色(ABC)法檢測(cè)肝臟組織細(xì)胞色素P4502E1(CYP2E1)含量及分布;逆轉(zhuǎn)錄-聚合酶鏈?zhǔn)椒磻?yīng)(RT-PCR)法檢測(cè)過(guò)氧化物酶體增殖劑活化受體α(PPARα)mRNA表達(dá)。結(jié)果:與正常組比較,模型組大鼠血清ALT,AST,TG,TC水平及FBG,FINS,TNF-α及IL-6含量明顯升高,HDL-C,IL-10含量明顯降低,肝組織SOD活性明顯降低,MDA及CYP2E1含量明顯升高,肝臟PPARαmRNA表達(dá)明顯降低,均具有明顯的統(tǒng)計(jì)學(xué)差異(P0.05);與模型組比較,活血祛濕方各劑量組均能夠改善大鼠NASH模型各項(xiàng)血清生化指標(biāo),降低FBG,FINS水平,明顯提高肝臟PPARαmRNA表達(dá),明顯增加肝臟中SOD活性及IL-10的含量,明顯減少肝臟MDA,CYP2E1,TNF-α及IL-6含量,與模型組比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。病理結(jié)果顯示,肝臟組織病理?yè)p傷明顯改善。結(jié)論:活血祛濕方能夠有效多途徑治療NASH,改善胰島素抵抗,減少脂質(zhì)過(guò)氧化反應(yīng),抑制炎癥反應(yīng)可能是其治療NASH的機(jī)制。
[Abstract]:Objective: to observe the therapeutic effect of different doses of Huoxue Qushi recipe on the model of non-alcoholic fatty hepatitis induced by purified high-fat diet in rats, and to explore the mechanism of Huoxue Qushi prescription in treating NASH. Methods: the NASH model of Wistar rats was prepared by purification of high fat diet for 8 weeks. The rats were randomly divided into rosiglitazone group (3 mg kg-1 d -1), high, middle and low dosage groups with high, middle and low doses of RPG 3 mg kg-1 d-1) and model group, and normal group. Normal group and model group were given the same amount of saline. Serum biochemical indexes were measured by colorimetry after 4 weeks of drug intervention. The contents of serum alanine aminotransferase (alt), aspartate aminotransferase (AST), triglyceride (TGN), total cholesterol (TC) and high density lipoprotein cholesterol (HDL-C) were determined by colorimetric method. Serum fasting blood glucose (FBGG), fasting insulin (FINSN), serum inflammatory factor tumor necrosis factor- 偽 (TNF- 偽), interleukin-10 (IL-10) and interleukin-6 (IL-6) were detected by radioimmunoassay, and the activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in liver tissue were detected by radioimmunoassay (RIA) and enzyme linked immunosorbent assay (Elisa). The histopathological changes of liver were observed by hematoxylin-eosin (HEH) staining, and the content and distribution of cytochrome P4502E1 (CYP2E1) were detected by ABC staining. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expression of peroxisome proliferator activated receptor 偽 -PPAR 偽 -PPAR 偽 mRNA. Results: compared with the normal group, the level of serum alt ASTGN TC, the content of FBGG FINSN TNF- 偽 and the content of IL-6 in the model group were significantly higher than those in the normal group. The activity of SOD in the liver decreased significantly, and the content of CYP2E1 and PPAR 偽 mRNA in the liver decreased significantly. Compared with the model group, each dose group of Huoxue Qushi recipe could improve the serum biochemical indexes, decrease the level of fins and increase the expression of PPAR 偽 mRNA in the liver. The activity of SOD and the content of IL-10 in the liver were significantly increased, and the contents of TNF- 偽 and IL-6 in the liver of MDA-CYP2E1 were significantly decreased compared with the model group (P 0.05). The pathological results showed that the pathological injury of liver tissue was obviously improved. Conclusion: Huoxue Qishi prescription can effectively treat NASH, improve insulin resistance, reduce lipid peroxidation and inhibit inflammatory reaction, which may be the mechanism of its treatment of NASH.
【作者單位】： 遼寧中醫(yī)藥大學(xué);遼寧中醫(yī)藥大學(xué)附屬醫(yī)院;
【基金】：遼寧省自然科學(xué)基金項(xiàng)目(201102142)
【分類(lèi)號(hào)】：R285.5;R-332

【相似文獻(xiàn)】

相關(guān)期刊論文 前5條

1 邵光秀;;自擬活血祛濕方治療頸內(nèi)動(dòng)脈系統(tǒng)TIA[J];實(shí)用心腦肺血管病雜志;2010年07期

2 崔晶;盧秉久;李瑩;;活血祛濕方對(duì)肝內(nèi)膽汁淤積型大鼠血清學(xué)指標(biāo)的影響[J];實(shí)用中醫(yī)內(nèi)科雜志;2011年11期

3 廖任宏,鄭海彥;活血祛濕方為主治療青光眼白內(nèi)障聯(lián)合術(shù)后脈絡(luò)膜脫離[J];中西醫(yī)結(jié)合眼科雜志;1997年02期

4 謝華;;補(bǔ)腎健脾活血祛濕方治療慢性腎炎80例臨床觀察[J];中國(guó)中醫(yī)藥科技;2012年06期

5 ;[J];;年期

相關(guān)博士學(xué)位論文 前1條

1 李嘉;健脾活血祛濕方對(duì)肝硬化腹水大鼠肝AQP8、9和線粒體的影響[D];廣州中醫(yī)藥大學(xué);2014年

相關(guān)碩士學(xué)位論文 前1條

1 崔晶;活血祛濕方對(duì)肝內(nèi)膽汁淤積型大鼠的治療作用研究[D];遼寧中醫(yī)藥大學(xué);2012年

，

本文編號(hào)：1890622